{"denomUnitsSelected":"Participants","description":"The number of induction and maintenance cycles received by patients randomized to the experimental therapy where SOS is observed. Only patients who receive all reporting period therapy or experience SOS will contribute to this outcome measure.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 202 days","title":"Occurrence of Sinusoidal Obstructive Disease (SOS) Associated With the Addition of Ganitumab to VDC/IE","type":"OTHER_PRE_SPECIFIED"}